

Thalidomide

Lancet, The

363, 1802-1811

DOI: [10.1016/s0140-6736\(04\)16308-3](https://doi.org/10.1016/s0140-6736(04)16308-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Molecular targeting: targeting angiogenesis in solid tumors. <i>Annals of Oncology</i> , 2004, 15, iv223-iv227.	0.6	17
4	A new opportunity for thalidomide? Further randomised controlled trial are necessary. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 607-608.	0.8	3
5	Post-radiation inflammatory reaction controlled with thalidomide and rofecoxib. <i>Clinical Oncology</i> , 2004, 16, 585-586.	0.6	3
6	Muscle metastases as initial manifestation of lung cancer. <i>Clinical Oncology</i> , 2004, 16, 586-587.	0.6	3
7	Gastrointestinal parasites in the immunocompromised. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 427-435.	1.3	73
8	Thalidomide in the management of epidermolysis bullosa pruriginosa. <i>British Journal of Dermatology</i> , 2005, 152, 1332-1334.	1.4	58
9	The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. <i>British Journal of Haematology</i> , 2005, 129, 3-17.	1.2	333
10	Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. <i>Leukemia</i> , 2005, 19, 873-875.	3.3	45
11	Thalidomide Enhances the Anti-Tumor Activity of Standard Chemotherapy in a Human Melanoma Xenotransplantation Model. <i>Journal of Investigative Dermatology</i> , 2005, 125, 201-206.	0.3	15
12	A case of disseminated Langerhans' cell histiocytosis treated with thalidomide. <i>European Journal of Haematology</i> , 2005, 74, 172-174.	1.1	10
13	Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis. <i>European Journal of Haematology</i> , 2005, 74, 273-274.	1.1	11
14	Thalidomide for advanced hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 1-4.	2.0	12
15	Targeted therapies for gynecologic malignancies. <i>Current Treatment Options in Oncology</i> , 2005, 6, 121-132.	1.3	3
16	Suppression of Urokinase Receptor Expression by Thalidomide Is Associated with Inhibition of Nuclear Factor $\kappa$ B Activation and Subsequently Suppressed Ovarian Cancer Dissemination. <i>Cancer Research</i> , 2005, 65, 10464-10471.	0.4	17
17	Thalidomide: present and future in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 25-31.	1.1	11
18	Immune deficiency in HIV-1 infection: novel therapeutic approaches targeting innate and adaptive responses. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 529-547.	1.3	2
19	Measuring Atopic Eczema Severity Visually. <i>Archives of Dermatology</i> , 2005, 141, 1146-51; discussion 1151.	1.7	56
20	Inmunomoduladores de empleo en enfermedades reumatológicas. Ciclofosfamida. Micofenolato. Thalidomida. Antipalúdicos. <i>Medicine</i> , 2005, 9, 1910-1916.	0.0	0

#	ARTICLE	IF	CITATIONS
21	Response of refractory osteosarcoma to thalidomide and celecoxib. <i>Lancet Oncology</i> , The, 2005, 6, 997-999.	5.1	16
22	Thalidomide in multiple myeloma. <i>Community Oncology</i> , 2005, 2, 111-113.	0.2	13
23	Thalidomideâ€”defining a roleâ€”finally. <i>Community Oncology</i> , 2005, 2, 113-115.	0.2	0
24	Use of angiogenesis inhibitors in tumour treatment. <i>European Journal of Cancer</i> , 2005, 41, 1109-1116.	1.3	71
25	Nuclear factor-Î² and liver carcinogenesis. <i>Cancer Letters</i> , 2005, 229, 157-169.	3.2	162
26	Current Therapy of Inflammatory Bowel Disease in Children. <i>Paediatric Drugs</i> , 2006, 8, 279-302.	1.3	95
27	Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 431-432.	0.9	10
29	Prenatal exposure to thalidomide, altered vasculogenesis, and CNS malformations. <i>Neuroscience</i> , 2006, 142, 267-283.	1.1	60
30	The use of thalidomide in androgen-independent prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 246-249.	0.8	13
32	Selective leukemic-cell killing by a novel functional class of thalidomide analogs. <i>Blood</i> , 2006, 108, 4126-4135.	0.6	28
33	Thalidomide for the Treatment of Refractory Necrobiosis Lipoidica. <i>Archives of Dermatology</i> , 2006, 142, 20-2.	1.7	23
34	Biochemistry of amino acid racemization and clinical application to musculoskeletal disease. <i>Clinical Biochemistry</i> , 2006, 39, 1112-1130.	0.8	55
35	The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 1-8.	2.3	9
36	Thalidomide does not interact with P-glycoprotein. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 599-606.	1.1	13
37	Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium. <i>Gynecologic Oncology</i> , 2006, 100, 160-165.	0.6	29
38	Thalidomide-Induced Severe Hepatotoxicity. <i>Pharmacotherapy</i> , 2006, 26, 1018-1022.	1.2	25
39	Pharmacotherapy of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 767-781.	0.9	4
40	Thalidomide in multiple myeloma: past, present and future. <i>Future Oncology</i> , 2006, 2, 577-589.	1.1	34

#	ARTICLE	IF	CITATIONS
41	Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. <i>European Journal of Heart Failure</i> , 2006, 8, 790-796.	2.9	13
42	Thalidomide reduces IL-18, IL-8 and TNF- $\alpha$ release from alveolar macrophages in interstitial lung disease. <i>European Respiratory Journal</i> , 2006, 28, 824-831.	3.1	69
43	Childhood Systemic Lupus Erythematosus: New and Old Treatments. <i>Current Pediatric Reviews</i> , 2006, 2, 165-171.	0.4	0
44	Antineovascular Agents in the Treatment of Eye Diseases. <i>Current Pharmaceutical Design</i> , 2006, 12, 2645-2660.	0.9	32
45	Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications. <i>Current Drug Metabolism</i> , 2006, 7, 677-685.	0.7	80
46	Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide. <i>Current Drug Metabolism</i> , 2006, 7, 431-454.	0.7	10
47	A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor- $\alpha$ Inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 82-104.	1.3	33
48	Error in Byline in: Measuring Atopic Eczema Severity Visually: Which Variables Are Most Important to Patients?. <i>Archives of Dermatology</i> , 2006, 142, 22.	1.7	1
49	A Novel Anticancer Effect of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1-Mediated Cell Invasion and Metastasis through Suppression of Nuclear Factor- $\kappa$ B. <i>Clinical Cancer Research</i> , 2006, 12, 7165-7173.	3.2	135
50	Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas. <i>Thyroid</i> , 2007, 17, 663-670.	2.4	79
51	Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy. <i>Oncologist</i> , 2007, 12, 465-477.	1.9	89
52	IgG multiple myeloma presented with ulcerative pyoderma gangrenosum. <i>Leukemia and Lymphoma</i> , 2007, 48, 1420-1422.	0.6	8
53	Potential Mechanisms of Benefit with Thalidomide in Chronic Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 127-134.	1.0	5
54	An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2007, 48, 46-55.	0.6	50
55	Modified DNA Aptamer That Binds the (R)-Isomer of a Thalidomide Derivative with High Enantioselectivity. <i>Journal of the American Chemical Society</i> , 2007, 129, 1456-1464.	6.6	153
56	Thalidomide inhibits pentylentetrazole-induced seizures. <i>Journal of the Neurological Sciences</i> , 2007, 258, 128-131.	0.3	24
57	Synthesis of Thalidomide. , 2007, , 73-97.		3
58	The evidence for the spinal segmental innervation of bone. <i>Clinical Anatomy</i> , 2007, 20, 956-960.	1.5	20

#	ARTICLE	IF	CITATIONS
59	Inhibition of 13-cis retinoic acid-induced gene expression of homeobox B7 by thalidomide. <i>International Journal of Cancer</i> , 2007, 121, 1205-1211.	2.3	6
60	Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. <i>International Journal of Cancer</i> , 2007, 121, 1697-1704.	2.3	27
61	Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5819-5824.	1.0	41
62	A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. <i>Pediatric Blood and Cancer</i> , 2007, 49, 261-265.	0.8	15
63	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , 2007, 99, 1047-1055.	1.3	45
64	Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 419-427.	1.9	50
65	Dermatologic therapeutics: thalidomide. A practical guide. <i>Dermatologic Therapy</i> , 2007, 20, 175-186.	0.8	16
66	The effect of methotrexate on the expression of cell adhesion molecules and activation molecule CD69 in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 334-339.	1.3	23
67	Reversal Effect of Thalidomide on Established Hepatic Cirrhosis in Rats via Inhibition of Nuclear Factor- $\kappa$ B/Inhibitor of Nuclear Factor- $\kappa$ B Pathway. <i>Archives of Medical Research</i> , 2007, 38, 15-27.	1.5	29
68	Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide. <i>European Journal of Haematology</i> , 2007, 79, 392-397.	1.1	17
69	Effects of geldanamycin and thalidomide on the Th1/Th2 cytokine balance in mice subjected to operative trauma. <i>Surgery</i> , 2007, 141, 490-500.	1.0	5
70	Early cerebrovascular and parenchymal events following prenatal exposure to the putative neurotoxin methylazoxymethanol. <i>Neurobiology of Disease</i> , 2007, 26, 481-495.	2.1	23
71	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 165-174.	1.1	45
73	Influence of the stationary phase on the stability of thalidomide and comparison of different methods for the quantification of thalidomide in tablets using high-temperature liquid chromatography. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 46, 625-630.	1.4	20
74	Thalidomide causes sinus bradycardia in ALS. <i>Journal of Neurology</i> , 2008, 255, 587-591.	1.8	29
75	Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 9708-9718.	1.4	60
76	Thalidomide and Its Analogs as Anticancer Agents. <i>Tzu Chi Medical Journal</i> , 2008, 20, 188-195.	0.4	1
77	Combined effects of prenatal inhibition of vasculogenesis and neurogenesis on rat brain development. <i>Neurobiology of Disease</i> , 2008, 32, 499-509.	2.1	18

#	ARTICLE	IF	CITATIONS
78	Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 60.	3.5	65
80	Glial Cells in ALS: The Missing Link?. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2008, 19, 441-459.	0.7	6
81	Enzymatic resolution and evaluation of enantiomers of cis-5 $\alpha$ -hydroxythalidomide. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 1540.	1.5	21
82	The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2405-2414.	1.9	8
83	Thalidomide Treatment for Refractory HIV-associated Colitis: A Case Series. <i>Clinical Infectious Diseases</i> , 2008, 47, 133-136.	2.9	38
84	A Phase II Study of Thalidomide and Temozolomide in Patients With Brain Metastases From Malignant Melanoma. Lymphopenia Correlates With Response. <i>Ecancermedicalsecience</i> , 2008, 2, 91.	0.6	2
85	A phase II study of thalidomide in patients with brain metastases from malignant melanoma. <i>Acta Oncologica</i> , 2008, 47, 1526-1530.	0.8	21
86	Molecular Targets and Targeted Therapies for Malignant Mesothelioma. <i>Current Medicinal Chemistry</i> , 2008, 15, 855-867.	1.2	33
87	Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects. <i>Cell Cycle</i> , 2008, 7, 1121-1127.	1.3	97
89	Thalidomide in the Treatment of Cancer Cachexia. <i>Journal of Palliative Care</i> , 2008, 24, 187-189.	0.4	8
90	Disseminated Intravascular Coagulation during Treatment with Thalidomide. A Case Report. <i>Tumori</i> , 2008, 94, 746-747.	0.6	1
91	Targeted therapy in melanoma. <i>Biologics: Targets and Therapy</i> , 0, , 475.	3.0	6
92	Anti-Inflammatory Thalidomide Improves Islet Grafts Survival and Functions in a Xenogenic Environment. <i>PLoS ONE</i> , 2009, 4, e6312.	1.1	11
93	Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5248-5254.	0.8	65
95	Thalidomide-Related Headache. <i>Dermatology</i> , 2009, 218, 285-285.	0.9	1
96	Thalidomide Inhibits Activation of Caspase-1. <i>Journal of Immunology</i> , 2009, 183, 5593-5599.	0.4	56
97	Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1049-1057.	3.0	126
98	Emerging Data with Antiangiogenic Therapies in Early and Advanced Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2009, 10, S7-S16.	1.1	15

#	ARTICLE	IF	CITATIONS
99	Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. <i>European Journal of Pharmacology</i> , 2009, 625, 6-22.	1.7	22
100	Thalidomide-induced limb defects: resolving a 50-year-old puzzle. <i>BioEssays</i> , 2009, 31, 1327-1336.	1.2	145
101	Hepatotoxicity as a rare but serious side effect of Thalidomide. <i>Annals of Hematology</i> , 2009, 88, 183-184.	0.8	6
102	In vitro anticancer property of a novel thalidomide analogue through inhibition of NF- $\kappa$ B activation in HL-60 cells. <i>Acta Pharmacologica Sinica</i> , 2009, 30, 134-140.	2.8	13
103	Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 8-13.	0.8	13
104	Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1. <i>Leukemia and Lymphoma</i> , 2009, 50, 109-113.	0.6	13
105	Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8573-8578.	3.3	220
106	A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. <i>Journal of Urology</i> , 2009, 181, 1104-1113.	0.2	41
107	Chemotherapy-induced diarrhoea. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 31-35.	0.5	58
108	White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patient access, medication safety, and impact on the health care system. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, 729-743.	0.7	18
109	Design and Synthesis of Thalidomide-Deoxyribonucleoside Chimeras. <i>Chemistry Letters</i> , 2009, 38, 1046-1047.	0.7	4
110	Chronic Graft versus Host Disease Pharmacology. , 0, , 101-116.		0
111	Thalidomide Attenuates Airway Hyperresponsiveness and Eosinophilic Inflammation in a Murine Model of Allergic Asthma. <i>Biological and Pharmaceutical Bulletin</i> , 2010, 33, 1028-1032.	0.6	12
112	Synthesis and Configurational Stability of (S)- and (R)-Deuteriothalidomides. <i>Chemical and Pharmaceutical Bulletin</i> , 2010, 58, 110-112.	0.6	26
113	Angiogenesis Inhibitors: Current Strategies and Future Prospects. <i>Ca-A Cancer Journal for Clinicians</i> , 2010, 60, 222-243.	157.7	413
115	Synthesis of Cyclic Imides from Simple Diols. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 6391-6395.	7.2	105
116	New thalidomide analogues derived through Sonogashira or Suzuki reactions and their TNF expression inhibition profiles. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 650-662.	1.4	30
117	Thalidomide for treatment of refractory epilepsy. <i>Epilepsy Research</i> , 2010, 92, 253-257.	0.8	15

#	ARTICLE	IF	CITATIONS
118	Thalidomide for the Control of Severe Paraneoplastic Pruritus Associated With Hodgkinâ€™s Disease. American Journal of Hospice and Palliative Medicine, 2010, 27, 486-487.	0.8	26
120	Thalidomide in lung cancer therapyâ€”what have we learned?. Nature Reviews Clinical Oncology, 2010, 7, 134-135.	12.5	8
122	Resolving a Double Standard for Risk Management of Thalidomide. Drug Safety, 2010, 33, 35-45.	1.4	10
123	Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression. International Immunopharmacology, 2010, 10, 806-811.	1.7	22
124	Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Letters, 2010, 291, 1-13.	3.2	78
125	Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models. Toxicology in Vitro, 2010, 24, 630-637.	1.1	12
126	A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 110, 188-195.	1.6	55
128	Identification of a Primary Target of Thalidomide Teratogenicity. Science, 2010, 327, 1345-1350.	6.0	1,614
129	Commentary on â€”Toxicity Testing in the 21st Century: A vision and a Strategyâ€™: Stem Cells and Cell-Cell Communication as Fundamental Targets in Assessing the Potential Toxicity of Chemicals. Human and Experimental Toxicology, 2010, 29, 21-29.	1.1	15
130	Identification of Racemization Sites Using Deuterium Labeling and Tandem Mass Spectrometry. Analytical Chemistry, 2010, 82, 6363-6369.	3.2	17
131	Evaluation of stability difference between asymmetric homochiral dimer in (S)-thalidomide crystal and symmetric heterochiral dimer in (RS)-thalidomide crystal. Phase Transitions, 2010, 83, 223-234.	0.6	9
132	Novel thalidomide analogues with potent NFÎ²B and TNF expression inhibition. MedChemComm, 2011, 2, 1073.	3.5	15
134	Efficacy of Thalidomide for Refractory Gastrointestinal Bleeding From Vascular Malformation. Gastroenterology, 2011, 141, 1629-1637.e4.	0.6	187
135	Update on new drugs in small cell lung cancer. Expert Opinion on Investigational Drugs, 2011, 20, 441-455.	1.9	14
136	The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Therapeutic Advances in Hematology, 2011, 2, 291-308.	1.1	104
137	Method Development for Pharmaceutical Chiral Chromatography. Separation Science and Technology, 2011, 10, 251-282.	0.0	4
138	Asymmetric Synthesis of Both Mirror Images of 3-Fluorothalidomide by Enantiodivergent Fluorination Using a Single, Cinchona Alkaloid. Organic Letters, 2011, 13, 470-473.	2.4	42
139	Stem Cells in Toxicology: Fundamental Biology and Practical Considerations. Toxicological Sciences, 2011, 120, S269-S289.	1.4	79



#	ARTICLE	IF	CITATIONS
140	Toxicologic pathology of the reproductive system. , 2011, , 1003-1026.		3
141	Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?. Current Molecular Pharmacology, 2011, 4, 26-61.	0.7	18
142	Gender differences and clinical trial design. Clinical Investigation, 2011, 1, 187-190.	0.0	3
143	The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: A pilot <i>in vivo</i> study. Journal of Digestive Diseases, 2011, 12, 349-356.	0.7	9
144	Thalidomide Attenuates Graft Arteriosclerosis of Aortic Transplant in a Rat Model. Transplantation Proceedings, 2011, 43, 2022-2026.	0.3	4
145	Chemical "Jekyll and Hyde"™s: small-molecule inhibitors of developmental signaling pathways. Chemical Society Reviews, 2011, 40, 4318.	18.7	30
146	Teratogenic effects of thalidomide: molecular mechanisms. Cellular and Molecular Life Sciences, 2011, 68, 1569-1579.	2.4	141
147	The gap junction as a "Biological Rosetta Stone" implications of evolution, stem cells to homeostatic regulation of health and disease in the Barker hypothesis. Journal of Cell Communication and Signaling, 2011, 5, 53-66.	1.8	32
148	Protective effect of thalidomide against N-methyl-D-aspartate-induced retinal neurotoxicity. Journal of Neuroscience Research, 2011, 89, 1596-1604.	1.3	7
149	Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism. FASEB Journal, 2011, 25, 2468-2483.	0.2	39
151	Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opinion on Drug Safety, 2011, 10, 3-8.	1.0	30
152	Fluorothalidomide: A Characterization of Maternal and Developmental Toxicity in Rabbits and Mice. Toxicological Sciences, 2011, 122, 157-169.	1.4	17
153	Stability of an extemporaneously prepared thalidomide suspension. American Journal of Health-System Pharmacy, 2012, 69, 56-58.	0.5	7
154	Idiopathic ileocolitis with perforation associated with HIV infection: thalidomide treatment. International Journal of STD and AIDS, 2012, 23, 830-832.	0.5	1
155	Imaging Features of Therapeutic Drug-induced Musculoskeletal Abnormalities. Radiographics, 2012, 32, 105-127.	1.4	34
156	Thalidomide: Chemistry, Therapeutic Potential and Oxidative Stress Induced Teratogenicity. Current Topics in Medicinal Chemistry, 2012, 12, 1436-1455.	1.0	26
157	The Role of IMiDs Alone or in Combination in Prostate Cancer. Clinical Genitourinary Cancer, 2012, 10, 141-146.	0.9	13
158	Effect of low-dose thalidomide on dopaminergic neuronal differentiation of human neural progenitor cells: A combined study of metabolomics and morphological analysis. NeuroToxicology, 2012, 33, 1375-1380.	1.4	12

#	ARTICLE	IF	CITATIONS
159	Obstetric Toxicology. <i>Emergency Medicine Clinics of North America</i> , 2012, 30, 977-990.	0.5	5
160	Development, validation and application of a sensitive LC-MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 902, 16-26.	1.2	11
161	A transgenic, mesodermal specific, Dkk1 mouse model recapitulates a spectrum of human congenital limb reduction defects. <i>Differentiation</i> , 2012, 83, 220-230.	1.0	5
162	Hyperemesis gravidarum in the Medical Birth Registry of Norway – a validity study. <i>BMC Pregnancy and Childbirth</i> , 2012, 12, 115.	0.9	21
163	Safety profile of enantiomers vs. racemic mixtures: it's the same?. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 886-889.	1.1	7
164	Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 491-498.	2.5	36
165	Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 323-329.	2.5	17
166	Thalidomide-induced acute cholestatic hepatitis: Case report and review of the literature. <i>Gastroenterology &amp; Hepatology</i> , 2012, 35, 560-566.	0.2	12
167	The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. <i>Lung Cancer</i> , 2012, 75, 248-254.	0.9	30
168	Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 297-320.	1.9	34
170	Castleman disease. <i>The Korean Journal of Hematology</i> , 2012, 47, 163.	0.7	37
171	Implications of Risk Evaluation and Mitigation Strategy (REMS) Programs for Managed Care Pharmacy. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 268-275.	2.2	0
172	Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents: TABLE 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 572-578.	1.3	44
173	Preparation, Characterization, and In Vitro Intestinal Permeability Evaluation of Thalidomide- $\beta$ -Hydroxypropyl- $\gamma$ -Cyclodextrin Complexes. <i>AAPS PharmSciTech</i> , 2012, 13, 118-124.	1.5	20
174	Synthesis of Triazolyl-Substituted Quinolizidine Imides. <i>Journal of the Chinese Chemical Society</i> , 2012, 59, 365-372.	0.8	14
175	Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 931-942.	1.1	56
176	Deciphering the mystery of thalidomide teratogenicity. <i>Congenital Anomalies (discontinued)</i> , 2012, 52, 1-7.	0.3	47
177	Thalidomide-induced phocomelia: – An old wound that still hurts –. <i>Open Medicine (Poland)</i> , 2012, 7, 523-524.	0.6	1

#	ARTICLE	IF	CITATIONS
178	Biomacromolecules as Ligands for Artificial Metalloenzymes. , 2013, , 737-761.		2
179	Therapeutic effects of thalidomide in hematologic disorders: a review. <i>Frontiers of Medicine</i> , 2013, 7, 290-300.	1.5	10
180	Role of thalidomide in the treatment of patients with multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S14-S22.	2.0	22
181	Mullerian agenesis associated with in-utero thalidomide exposure: A case report. <i>Middle East Fertility Society Journal</i> , 2013, 18, 214-216.	0.5	1
183	Thalidomide is not able to inhibit radiation-induced heart disease. <i>International Journal of Radiation Biology</i> , 2013, 89, 685-691.	1.0	15
184	Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands. <i>Dalton Transactions</i> , 2013, 42, 2008-2014.	1.6	62
185	Cereblon: molekularny cel leków immunomodulujących. <i>Acta Haematologica Polonica</i> , 2013, 44, 200-207.	0.1	0
186	Indicaciones de talidomida y sus derivados en dermatología. <i>Piel</i> , 2013, 28, 606-613.	0.0	0
187	Early Births and Congenital Birth Defects. <i>Clinics in Perinatology</i> , 2013, 40, 629-644.	0.8	13
189	Novel therapies for oral lichen planus. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 721-727.	1.4	53
190	Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12703-12708.	3.3	64
191	Thalidomide Embryopathy: An Enigmatic Challenge. <i>ISRN Developmental Biology</i> , 2013, 2013, 1-18.	1.4	45
192	Thalidomide distinctly affected TNF- $\alpha$ , IL-6 and MMP secretion by an ovarian cancer cell line (SKOV-3) and primary ovarian cancer cells. <i>European Cytokine Network</i> , 2013, 24, 122-129.	1.1	12
193	The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis. <i>Wspolczesna Onkologia</i> , 2014, 1, 39-47.	0.7	3
194	Enantioresolution of Chiral Derivatives of Xanthenes on Different Types of Liquid Chromatography Stationary Phases: A Comparative Study. <i>Current Chromatography</i> , 2014, 1, 139-150.	0.1	4
195	Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma. <i>Genes and Cancer</i> , 2014, 5, 127-141.	0.6	7
197	High Risk for Major Nonlimb Anomalies Associated with Lower-Limb Deficiency. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014, 96, 1898-1904.	1.4	19
198	Caprine pancreatic islet xenotransplantation into diabetic immunosuppressed BALB /c mice. <i>Xenotransplantation</i> , 2014, 21, 174-182.	1.6	11

#	ARTICLE	IF	CITATIONS
199	Thalidomide mimics uridine binding to an aromatic cage in cereblon. <i>Journal of Structural Biology</i> , 2014, 188, 225-232.	1.3	54
200	Epidermolysis bullosa pruriginosa showing good response to low-dose thalidomide - a report of two cases. <i>Dermatologic Therapy</i> , 2014, 27, 60-63.	0.8	11
201	Thalidomide in the Treatment of Immune Reconstitution Inflammatory Syndrome in HIV Patients with Neurological Tuberculosis. <i>AIDS Patient Care and STDs</i> , 2014, 28, 567-569.	1.1	13
202	DiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections. <i>Nucleic Acids Research</i> , 2014, 42, W137-W146.	6.5	106
203	Mucosal Healing With Thalidomide in Refractory Crohn's Disease Patients Intolerant of Anti-TNF Drugs. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 530-533.	1.1	15
204	Thalidomide and Refractory Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 476-477.	1.1	5
205	Phthaloyl amino acids as anti-inflammatory and immunomodulatory prototypes. <i>Medicinal Chemistry Research</i> , 2014, 23, 1701-1708.	1.1	16
206	Nitric oxide mediates the anticonvulsant effects of thalidomide on pentylenetetrazole-induced clonic seizures in mice. <i>Epilepsy and Behavior</i> , 2014, 34, 99-104.	0.9	26
208	Synthesis of Cyclic Imides from Nitriles and Diols Using Hydrogen Transfer as a Substrate-Activating Strategy. <i>Organic Letters</i> , 2014, 16, 4404-4407.	2.4	34
209	Boon or bust? Heidegger, disability aesthetics and the thalidomide memorial. <i>Disability and Society</i> , 2014, 29, 751-762.	1.4	8
210	Brain Arteriovenous Malformation Modeling, Pathogenesis, and Novel Therapeutic Targets. <i>Translational Stroke Research</i> , 2014, 5, 316-329.	2.3	54
211	Bortezomib-Contained Chemotherapy and Thalidomide Combined With CHOP (Cyclophosphamide,) Tj ETQq1 1 0.784314 rgBT /Over Report and Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e145-e150.	0.2	35
212	Thalidomide Ameliorates Inflammation and Vascular Injury but Aggravates Tubular Damage in the Irradiated Mouse Kidney. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 599-606.	0.4	9
213	Strategic medical writing in the post-authorisation phase. <i>Medical Writing</i> , 2014, 23, 267-272.	0.0	1
214	Stereoselective Synthesis of (R)-Methylthalidomide by Piperidine One Ring Assembly Approach. <i>Chirality</i> , 2015, 27, 619-624.	1.3	3
215	Successful treatment of <i>Cryptococcus neoformans</i> immune reconstitution inflammatory syndrome in an immunocompetent host using thalidomide. <i>Medical Mycology Case Reports</i> , 2015, 7, 12-14.	0.7	19
216	Phase II trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 865-868.	0.4	7
217	The Efficiency of India's Patent Layering Regime - Section 3(d) from Scientific Terminology to Patenting Implications. <i>IIC International Review of Intellectual Property and Competition Law</i> , 2015, 46, 665-681.	0.3	0

#	ARTICLE	IF	CITATIONS
218	Heidegger, subjectivity, disability. <i>Subjectivity</i> , 2015, 8, 224-242.	0.2	3
219	Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. <i>Haemophilia</i> , 2015, 21, 419-429.	1.0	26
220	Anti-tumor necrosis factor monoclonal antibody for steroid-dependent TB-IRIS in AIDS. <i>Aids</i> , 2015, 29, 1117-1119.	1.0	10
221	Cobicistatâ€™vinblastine interaction and severe peripheral neuropathy. <i>Aids</i> , 2015, 29, 1120-1121.	1.0	4
222	Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1739-1749.	0.9	28
223	Acute myocardial infarction following thalidomide treatment for AIDS-related ulcers. <i>Aids</i> , 2015, 29, 1119-1120.	1.0	1
224	Tumour Angiogenesis and Angiogenic Inhibitors: A Review. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015, 9, XE01-XE05.	0.8	113
225	Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model. <i>Chinese Medical Journal</i> , 2015, 128, 3050-3054.	0.9	17
226	Prediction of Drug Indications Based on Chemical Interactions and Chemical Similarities. <i>BioMed Research International</i> , 2015, 2015, 1-14.	0.9	3
227	Water-Soluble Ruthenium(II) Complexes with Chiral 4-(2,3-Dihydroxypropyl)-formamide Oxoaporphine (FOA): In Vitro and in Vivo Anticancer Activity by Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Induction of Tumor Cell Apoptosis. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4771-4789.	2.9	108
228	Thalidomideâ€™induced teratogenesis: History and mechanisms. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2015, 105, 140-156.	3.6	610
229	Self-disproportionation of enantiomers of thalidomide and its fluorinated analogue via gravity-driven achiral chromatography: mechanistic rationale and implications. <i>Chemical Science</i> , 2015, 6, 1043-1048.	3.7	35
230	Solid Phase Behavior in the Chiral Systems of Various 2-Hydroxy-2-phenylacetic Acid (Mandelic Acid) Derivatives. <i>Journal of Chemical &amp; Engineering Data</i> , 2015, 60, 721-728.	1.0	7
231	Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. <i>Immunotherapy</i> , 2015, 7, 175-190.	1.0	13
232	Neuroprotective effect of thalidomide on MPTP-induced toxicity. <i>NeuroToxicology</i> , 2015, 47, 82-87.	1.4	17
233	Cognitive outcomes of prenatal antiepileptic drug exposure. <i>Epilepsy Research</i> , 2015, 114, 89-97.	0.8	25
234	The Thalidomide-Binding Domain of Cereblon Defines the CULT Domain Family and Is a New Member of the $\beta$ -Tent Fold. <i>PLoS Computational Biology</i> , 2015, 11, e1004023.	1.5	34
235	The clinical implications of thalidomide in inflammatory bowel diseases. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 699-708.	1.3	16

#	ARTICLE	IF	CITATIONS
236	Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2228-2237.	1.9	28
237	Reproductive Toxicology. , 0, , .		1
238	Effective treatment of gastrointestinal bleeding with thalidomide - Chances and limitations. <i>World Journal of Gastroenterology</i> , 2016, 22, 3158.	1.4	32
239	Cardio-respiratory development in bird embryos: new insights from a venerable animal model. <i>Revista Brasileira De Zootecnia</i> , 2016, 45, 709-728.	0.3	22
240	Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2016, 105, 946-951.	0.7	10
241	Back to the future: Research renewed on the clinical utility of psychedelic drugs. <i>Journal of Psychopharmacology</i> , 2016, 30, 1198-1200.	2.0	7
242	Anticancer effect of thalidomide in vitro on human osteosarcoma cells. <i>Oncology Reports</i> , 2016, 36, 3545-3551.	1.2	9
243	Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model. <i>Scientific Reports</i> , 2016, 6, 21419.	1.6	36
244	Possible alternative therapies for oral lichen planus cases refractory to steroid therapies. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 496-509.	0.2	42
246	Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. <i>International Journal of Hematology</i> , 2016, 104, 293-299.	0.7	59
247	Development of Shelf-Stable Reagents for Fluoro-Functionalization Reactions. <i>Bulletin of the Chemical Society of Japan</i> , 2016, 89, 1307-1320.	2.0	50
248	Role of Thalidomide on the Expression of OX40, 4-1BB, and GITR in T Cell Subsets. <i>Transplantation Proceedings</i> , 2016, 48, 1270-1274.	0.3	12
249	Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions. <i>European Journal of Pharmacology</i> , 2016, 793, 76-81.	1.7	93
250	Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide. <i>Medicine (United States)</i> , 2016, 95, e4606.	0.4	19
251	Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. <i>Briefings in Bioinformatics</i> , 2016, 18, bbw051.	3.2	57
252	Modulation of radiation-induced oral mucositis by thalidomide. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 561-568.	1.0	13
253	Thalidomide for the treatment of chronic refractory pruritus. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 363-369.	0.6	46
254	Modulation of cereblon levels by anti-myeloma agents. <i>Leukemia and Lymphoma</i> , 2016, 57, 167-176.	0.6	7

#	ARTICLE	IF	CITATIONS
255	Chirality Switching Via Rotation of Bilayer Fourfold Meta-Structure. <i>Plasmonics</i> , 2017, 12, 83-87.	1.8	4
256	A new mammalian model system for thalidomide teratogenesis: <i>Monodelphis domestica</i> . <i>Reproductive Toxicology</i> , 2017, 70, 126-132.	1.3	10
257	Controlled propulsion and separation of helical particles at the nanoscale. <i>Soft Matter</i> , 2017, 13, 2148-2154.	1.2	5
258	Treating the dysfunctional placenta. <i>Journal of Endocrinology</i> , 2017, 234, R81-R97.	1.2	62
259	Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1382-1389.e1.	2.4	17
260	A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders. <i>Trends in Molecular Medicine</i> , 2017, 23, 348-361.	3.5	65
261	Solid dispersions enhance solubility, dissolution, and permeability of thalidomide. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 511-518.	0.9	7
262	Thalidomide induces apoptosis in undifferentiated human induced pluripotent stem cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2017, 53, 841-851.	0.7	7
263	Drug repurposing in cancer. <i>Pharmacological Research</i> , 2017, 124, 74-91.	3.1	248
264	Antiinflammation and Antioxidant Effects of Thalidomide on Pulmonary Fibrosis in Mice and Human Lung Fibroblasts. <i>Inflammation</i> , 2017, 40, 1836-1846.	1.7	17
265	Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats - an experimental study. <i>Transplant International</i> , 2017, 30, 1181-1189.	0.8	3
266	Chirality and Chiroptical Effects in Metal Nanostructures: Fundamentals and Current Trends. <i>Advanced Optical Materials</i> , 2017, 5, 1700182.	3.6	265
267	Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets. <i>Immunology</i> , 2017, 152, 628-637.	2.0	15
268	Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients. <i>Medicine (United States)</i> , 2017, 96, e6540.	0.4	9
269	Synthesis of Cyclic Imides by Acceptorless Dehydrogenative Coupling of Diols and Amines Catalyzed by a Manganese Pincer Complex. <i>Journal of the American Chemical Society</i> , 2017, 139, 11722-11725.	6.6	135
270	Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety. <i>EBioMedicine</i> , 2017, 23, 59-67.	2.7	21
271	Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1810-1816.	0.9	11
272	Toxicologic Pathology of the Reproductive System. , 2017, , 1209-1241.		10



#	ARTICLE	IF	CITATIONS
273	Repurposing ospemifene for potentiating an antigen-specific immune response. <i>Menopause</i> , 2017, 24, 437-451.	0.8	3
274	Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 210-216.	0.7	10
275	Vertebrate embryos as tools for anti-angiogenic drug screening and function. <i>Reproductive Toxicology</i> , 2017, 70, 49-59.	1.3	11
276	Thalidomide attenuates the development and expression of antinociceptive tolerance to $\mu$ -opioid agonist morphine through l-arginine-iNOS and nitric oxide pathway. <i>Biomedicine and Pharmacotherapy</i> , 2017, 85, 493-502.	2.5	18
277	The Emperor's New Surgery. <i>Techniques in Hand and Upper Extremity Surgery</i> , 2017, 21, 127-127.	0.3	0
278	The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine. <i>Current Molecular Medicine</i> , 2017, 17, 108-117.	0.6	15
279	OFF-LABEL PRESCRIBING. POSSIBLE CAUSES, TYPES AND CONSEQUENCES. LEGAL REGULATION IN THE RUSSIAN FEDERATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 667-674.	0.3	15
281	Nuclear Factor of Activated T Cells and Cytokines Gene Expression of the T Cells in AIDS Patients with Immune Reconstitution Inflammatory Syndrome during Highly Active Antiretroviral Therapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-7.	1.4	5
282	A standardized human embryoid body platform for the detection and analysis of teratogens. <i>PLoS ONE</i> , 2017, 12, e0171101.	1.1	20
283	Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 1141-1155.	0.8	11
284	Physiology and Pathology of Drug Hypersensitivity: Role of Human Leukocyte Antigens. , 0, , .		4
285	Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition. <i>Acta Tropica</i> , 2018, 183, 134-141.	0.9	44
286	Thalidomide induces apoptosis during early mesodermal differentiation of human induced pluripotent stem cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2018, 54, 231-240.	0.7	5
287	Human and mouse artificial chromosome technologies for studies of pharmacokinetics and toxicokinetics. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, 17-30.	1.1	19
288	Structural basis of thalidomide enantiomer binding to cereblon. <i>Scientific Reports</i> , 2018, 8, 1294.	1.6	77
289	A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay. <i>Biomedical Chromatography</i> , 2018, 32, e4240.	0.8	4
291	Thalidomide Reduces Hemorrhage of Brain Arteriovenous Malformations in a Mouse Model. <i>Stroke</i> , 2018, 49, 1232-1240.	1.0	56
292	Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 499-505.	1.4	0



#	ARTICLE	IF	CITATIONS
293	Emerging role of thalidomide in the treatment of gastrointestinal bleeding. <i>Frontline Gastroenterology</i> , 2018, 9, 98-104.	0.9	10
294	Oxidative stress during development: Chemical-induced teratogenesis. <i>Current Opinion in Toxicology</i> , 2018, 7, 110-115.	2.6	13
295	Repurposing sertraline sensitizes non- $\alpha$ -small cell lung cancer cells to erlotinib by inducing autophagy. <i>JCI Insight</i> , 2018, 3, .	2.3	51
296	Reply to M.F. Chong et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 828-829.	0.8	1
297	Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice. <i>Journal of Toxicological Sciences</i> , 2018, 43, 671-684.	0.7	8
298	Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers. <i>Scientific Reports</i> , 2018, 8, 17131.	1.6	82
299	Reviewing the role of healthy volunteer studies in drug development. <i>Journal of Translational Medicine</i> , 2018, 16, 336.	1.8	32
300	Continuous-Flow Left Ventricular Assist Device-Related Gastrointestinal Bleeding. <i>Cardiology Clinics</i> , 2018, 36, 519-529.	0.9	18
301	The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. <i>Journal of Laryngology and Otology</i> , 2018, 132, 866-871.	0.4	19
303	Thalidomide remodels developing heart in chick embryo: discovery of a thalidomide mediated hematoma in heart muscle. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 1093-1105.	1.4	11
304	Targeting pericytes for therapeutic approaches to neurological disorders. <i>Acta Neuropathologica</i> , 2018, 136, 507-523.	3.9	165
305	Neuro- and nephroprotective effect of grape seed proanthocyanidin extract against carboplatin and thalidomide through modulation of inflammation, tumor suppressor protein p53, neurotransmitters, oxidative stress and histology. <i>Toxicology Reports</i> , 2018, 5, 568-578.	1.6	28
306	von Willebrand factor regulation of blood vessel formation. <i>Blood</i> , 2018, 132, 132-140.	0.6	148
307	Immunomodulatory drugs alleviate $\alpha$ -dopa-induced dyskinesia in a rat model of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1818-1830.	2.2	44
308	Computational elucidation of the binding mechanisms of curcumin analogues as bacterial RecA inhibitors. <i>RSC Advances</i> , 2019, 9, 19869-19881.	1.7	5
309	Neutrophil extracellular traps contribute to the pathogenesis of leprosy type 2 reactions. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007368.	1.3	13
310	Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 11, 177-179.	1.4	1
311	Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide. <i>International Journal of STD and AIDS</i> , 2019, 30, 1131-1135.	0.5	7

#	ARTICLE	IF	CITATIONS
312	Single-Agent Thalidomide for Treatment of Malignant Paraganglioma of the Organ of Zuckerkandl. Case Reports in Medicine, 2019, 2019, 1-4.	0.3	2
313	Molecular mechanisms of cereblon-based drugs. , 2019, 202, 132-139.		46
314	Adverse events in patients with leprosy on treatment with thalidomide. Revista Da Sociedade Brasileira De Medicina Tropical, 2019, 52, e20180385.	0.4	6
315	Thalidomide ameliorate graft chronic rejection in an allogenic kidney transplant model. International Immunopharmacology, 2019, 71, 32-39.	1.7	6
316	Phthalimide Derivative Shows Anti-angiogenic Activity in a 3D Microfluidic Model and No Teratogenicity in Zebrafish Embryos. Frontiers in Pharmacology, 2019, 10, 349.	1.6	20
317	Anti-cytokines in the treatment of cancer cachexia. Annals of Palliative Medicine, 2019, 8, 67-79.	0.5	42
318	Thalidomide for the treatment of angiodysplasia-related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?. Clinical Case Reports (discontinued), 2019, 7, 2363-2367.	0.2	2
319	Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. Future Medicinal Chemistry, 2019, 11, 2595-2620.	1.1	20
320	In silico study on identification of novel MALT1 allosteric inhibitors. RSC Advances, 2019, 9, 39338-39347.	1.7	5
321	Enantioselective electrophilic fluorination of $\beta$ -aryl-tetralones using a preparation of N-fluoroammonium salts of cinchonine. Journal of Fluorine Chemistry, 2019, 217, 72-79.	0.9	9
322	The teratogenic effects of thalidomide on limbs. Journal of Hand Surgery: European Volume, 2019, 44, 88-95.	0.5	53
323	Benefit-Risk Management. , 2019, , 161-180.		0
324	Anti- $\beta$ -amyloid aggregation activity of enantiomeric furo lactone-type lignans from Archidendron clypearia (Jack) I.C.N.. Natural Product Research, 2020, 34, 456-463.	1.0	3
325	Synthesis of N-unsubstituted cyclic imides from anhydride with urea in deep eutectic solvent (DES) choline chloride/urea. Chemical Papers, 2020, 74, 1351-1357.	1.0	2
326	CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease. Journal of Digestive Diseases, 2020, 21, 98-103.	0.7	2
327	Anti-leishmanial activity and cytotoxicity of a series of tris-aryl Sb(V) mandelate cyclometallate complexes. Journal of Inorganic Biochemistry, 2020, 203, 110932.	1.5	13
328	Thalidomide leads to mandible hypoplasia through inhibiting angiogenesis and secondary hemorrhage in the fetal craniofacial region in rabbits. Toxicology Letters, 2020, 319, 250-255.	0.4	2
329	Thalidomide as a potential adjuvant treatment for paraneoplastic pemphigus: A single-center experience. Dermatologic Therapy, 2020, 33, e14353.	0.8	5

#	ARTICLE	IF	CITATIONS
330	Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008678.	1.3	18
331	NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword. <i>Frontiers in Immunology</i> , 2020, 11, 1444.	2.2	148
332	Medication-related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2767-2776.	1.1	16
333	Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2935.	1.0	8
334	Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2020, 11, 572870.	1.6	72
335	Chirality Transfer from Sub-Nanometer Biochemical Molecules to Sub-Micrometer Plasmonic Metastructures: Physicochemical Mechanisms, Biosensing, and Bioimaging Opportunities. <i>Advanced Materials</i> , 2020, 32, e1907151.	11.1	81
336	Stimuli-Responsive Aliphatic Polycarbonate Nanocarriers for Tumor-Targeted Drug Delivery. <i>Polymers</i> , 2020, 12, 2890.	2.0	17
337	Interactions between Amyloid- $\beta$ Proteins and Human Brain Pericytes: Implications for the Pathobiology of Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 1490.	1.0	26
338	Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1765.	1.0	22
339	Molecular mechanisms of thalidomide and its derivatives. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2020, 96, 189-203.	1.6	55
340	How progressive cancer endangers the heart: an intriguing and underestimated problem. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 535-552.	2.7	11
341	Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy. <i>Seminars in Cancer Biology</i> , 2020, 67, 53-60.	4.3	9
342	Neuroprotection by the Immunomodulatory Drug Pomalidomide in the <i>Drosophila</i> LRRK2WD40 Genetic Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 31.	1.7	13
343	The role of teratogens in neural crest development. <i>Birth Defects Research</i> , 2020, 112, 584-632.	0.8	19
344	Cosmetic treatment in patients with autoimmune connective tissue diseases. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 343-363.	0.6	15
345	Mining Complex Biomedical Literature for Actionable Knowledge on Rare Diseases. <i>Human Perspectives in Health Sciences and Technology</i> , 2020, , 77-94.	0.2	4
346	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. <i>Seminars in Cancer Biology</i> , 2021, 68, 209-229.	4.3	39
347	A novel chiral polyester composite membrane: Preparation, enantioseparation of chiral drugs and molecular modeling evaluation. <i>Separation and Purification Technology</i> , 2021, 255, 117717.	3.9	22

#	ARTICLE	IF	CITATIONS
348	Synthesis of cytotoxic spirocyclic imides from a biomass-derived oxanorbornene. <i>Tetrahedron</i> , 2021, 77, 131754.	1.0	2
349	MIP as Drug Delivery Systems of Anticancer Agents. , 2021, , 133-152.		0
350	Systemic Inflammation Associated with Immune Reconstitution Inflammatory Syndrome in Persons Living with HIV. <i>Life</i> , 2021, 11, 65.	1.1	11
351	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. , 2021, , 27-89.		0
352	Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis. <i>Bioengineered</i> , 2021, 12, 3647-3661.	1.4	5
353	Structure-activity relationship study of the anti-obesity natural product yoshinone A. <i>Chirality</i> , 2021, 33, 226-232.	1.3	1
354	Manifesting Simultaneous Optical Spin Conservation and Spin Isolation in Diatomic Metasurfaces. <i>Advanced Optical Materials</i> , 2021, 9, 2002002.	3.6	39
355	Anatomical Considerations of Embryology and Development of the Musculoskeletal System: Basic Notions for Musculoskeletal Radiologists. <i>Seminars in Musculoskeletal Radiology</i> , 2021, 25, 003-021.	0.4	3
356	Chiral Dualism as a Unifying Principle in Molecular Biophysics. <i>Biophysica</i> , 2021, 1, 22-37.	0.6	4
357	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <i>European Journal of Pharmacology</i> , 2021, 895, 173890.	1.7	86
358	TNFR2: Role in Cancer Immunology and Immunotherapy. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 103-122.	2.7	20
359	Antidepressants and Antipsychotic Agents as Repurposable Oncological Drug Candidates. <i>Current Medicinal Chemistry</i> , 2021, 28, 2137-2174.	1.2	10
360	A comprehensive review on anticancer mechanism of bazedoxifene. <i>Biotechnology and Applied Biochemistry</i> , 2022, 69, 767-782.	1.4	10
361	La catástrofe de la talidomida y su importancia en la seguridad de los medicamentos. <i>Avances En Enfermería</i> , 2021, 39, 155-156.	0.3	0
362	Advancing targeted protein degradation for cancer therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 638-654.	12.8	251
363	Thalidomide Attenuates Colitis and Is Associated with the Suppression of M1 Macrophage Polarization by Targeting the Transcription Factor IRF5. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3803-3812.	1.1	7
364	ECCO Topical Review: Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1605-1620.	0.6	16
365	Comparison of Drug Withdrawal Processes in the U.S. and Other Nations. <i>Innovations in Pharmacy</i> , 2021, 12, 5.	0.2	2

#	ARTICLE	IF	CITATIONS
366	Establishment of an in vitro method of rabbit embryo toxicity with toxicokinetics study. Journal of Applied Toxicology, 2021, , .	1.4	0
367	Pharmacotherapy for Behçet's Disease and the Risk of Malignancy. Frontiers in Pharmacology, 2021, 12, 661150.	1.6	7
368	Thalidomide affects limb formation and multiple myeloma related genes in human induced pluripotent stem cells and their mesoderm differentiation. Biochemistry and Biophysics Reports, 2021, 26, 100978.	0.7	2
369	Giant chiro-optical responses in multipolar-resonances-based single-layer dielectric metasurfaces. Photonics Research, 2021, 9, 1667.	3.4	71
370	Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis. Clinical Oral Investigations, 2021, 25, 5149-5169.	1.4	10
371	O-Alkylation Redirected Condensation of 5-Hydroxy-1,2-oxazine-6-ones with Primary Amines for Synthesis of 5-Hydroxyiminopyridine-2,6(1H,3H)-diones. ChemistrySelect, 2021, 6, 8938-8941.	0.7	3
372	A Targeted Nanosystem for Detection of Inflammatory Diseases via Fluorescent/Optoacoustic Imaging and Therapy via Modulating Nrf2/NF-κB Pathways. Small, 2021, 17, e2102598.	5.2	12
373	Optical Activity in Third-Harmonic Rayleigh Scattering: A New Route for Measuring Chirality. Laser and Photonics Reviews, 2021, 15, 2100235.	4.4	17
374	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. Cancers, 2021, 13, 4787.	1.7	14
375	Complete remission of intractable bullous erythema multiforme with thalidomide therapy: A case series. JAAD Case Reports, 2021, 15, 76-79.	0.4	0
376	Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment. Cancer Treatment and Research Communications, 2021, 27, 100336.	0.7	24
377	Continuous flow asymmetric synthesis of chiral active pharmaceutical ingredients and their advanced intermediates. Green Chemistry, 2021, 23, 6117-6138.	4.6	62
379	Tumour Necrosis Factor " Misnomer and Therapeutic Target. , 2009, , 425-448.		1
380	Population-Based Surveillance for Rare Congenital and Inherited Disorders: Models and Challenges. Advances in Experimental Medicine and Biology, 2010, 686, 133-150.	0.8	5
381	Treatment of Castration-Resistant Prostate Cancer. , 2012, , 2954-2971.e4.		3
382	Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?. EBioMedicine, 2017, 24, 20-21.	2.7	3
384	Molecular Chirality Detection with Periodic Arrays of Three-Dimensional Twisted Metamaterials. ACS Applied Materials & Interfaces, 2021, 13, 1152-1157.	4.0	16
385	Crystal structure of the thalidomide analog (3a-R*,7a-S*)-2-(2,6-dioxopiperidin-3-yl)hexahydro-1H-isoindole-1,3(2H)-dione. Acta Crystallographica Section E: Crystallographic Communications, 2018, 74, 1595-1598.	0.2	1

#	ARTICLE	IF	CITATIONS
386	Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?. <i>Journal of Small Animal Practice</i> , 2018, 59, 85-91.	0.5	22
387	Optical activity temperature-dependent measurements of chiral solutions using Mueller matrix spectroscopic ellipsometry. , 2018, ,		2
388	Supercritical Fluid Chromatography for Chiral Method Development Screening and Analysis. , 2014, , 161-186.		4
389	Pre-Concentration Approaches Combined with Capillary Electrophoresis in Bioanalysis of Chiral Cardiovascular Drugs. <i>Pharmaceutical Sciences</i> , 2015, 21, 229-243.	0.8	25
390	Human Adult Stem Cells as the Target Cells for the Initiation of Carcinogenesis and for the Generation of "Cancer Stem Cells". <i>International Journal of Stem Cells</i> , 2008, 1, 8-26.	0.8	25
391	Retroperitoneal unicentric Castleman's disease (giant lymph node hyperplasia): case report. <i>Sao Paulo Medical Journal</i> , 2007, 125, 253-255.	0.4	8
392	Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 28938-28948.	0.8	11
393	Neuropharmacological Screening of Chiral and Non-chiral Phthalimide- Containing Compounds in Mice: <i>in vivo</i> and <i>in silico</i> Experiments. <i>Medicinal Chemistry</i> , 2019, 15, 102-118.	0.7	5
394	Thalidomide attenuates the hyporesponsiveness of isolated atria to chronotropic stimulation in BDL rats: The involvement of TNF- $\alpha$ , IL-6 inhibition, and SOCS1 activation. <i>Iranian Journal of Basic Medical Sciences</i> , 2019, 22, 1259-1266.	1.0	7
395	Mental Disorders in People Affected by Thalidomide. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2017, 114, 168-174.	0.6	13
396	Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by <i>Leishmania major</i> in BALB/c mice. <i>Korean Journal of Parasitology</i> , 2006, 44, 55.	0.5	9
397	Angiogenesis and vascular malformations: Antiangiogenic drugs for treatment of gastrointestinal bleeding. <i>World Journal of Gastroenterology</i> , 2007, 13, 5979.	1.4	57
398	Thalidomide induces mucosal healing in Crohn's disease: Case report. <i>World Journal of Gastroenterology</i> , 2011, 17, 5028.	1.4	10
399	Perspective: Does personalized medicine hold the future for medicine?. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2015, 7, 239.	0.2	64
400	Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. <i>World Journal of Hepatology</i> , 2017, 9, 613.	0.8	35
401	Cachexia Associated with AIDS. , 2005, , 143-164.		0
402	Regulating the Master Regulator NF- $\kappa$ B. , 2006, , 195-221.		0
403	Angiogenesis Inhibitors in Prostate Cancer. <i>Translational Medicine Series</i> , 2006, , 127-141.	0.0	0

#	ARTICLE	IF	CITATIONS
404	Antiangiogenic Therapy for Lung Cancer: Small-Molecule Inhibitors. Translational Medicine Series, 2007, , 45-72.	0.0	0
405	Thalidomid. Pharma-Kritik (discontinued), 2008, 30, .	0.0	0
406	Immunoregulatory Drugs. , 2009, , 909-927.		1
407	Angiogenesis Inhibitors in Lung Cancer. , 2010, , 227-252.		1
408	Pharmaceutical drug safety. , 2010, , 263-279.		0
409	Investigational Angiogenesis Inhibitors. , 2010, , 225-232.		1
411	Systemic Treatment for Unresectable Thyroid Carcinoma: Comprehensive Approach. , 2012, , 383-397.		0
412	Principles of Chemotherapy. , 2012, , 165-179.		0
413	Risk in Medicine: Early Developments to the 1980s. , 2014, , 32-47.		0
414	Significance of Fractionated Administration of Thalidomide Combined With $\hat{I}^3$ -Ray Irradiation in Terms of Local Tumor Response and Lung Metastasis. World Journal of Oncology, 2014, 5, 155-165.	0.6	3
415	The Pathogenesis and Management of Pruritus in Epidermolysis Bullosa. , 2015, , 719-727.		0
417	Recent Advancements in Oral Lichen Planus Management: An Overview. World Journal of Dentistry, 2018, 9, 249-251.	0.1	1
418	Assessing the Potential Role of Calcitonin in Cancer. World Journal of Dentistry, 2018, 9, 253-254.	0.1	0
420	Cancer Immunotherapy. , 2020, , 321-355.		0
421	Centromere identity and function put to use: construction and transfer of mammalian artificial chromosomes to animal models. Essays in Biochemistry, 2020, 64, 185-192.	2.1	3
422	Knowledge-based approaches to drug discovery for rare diseases. Drug Discovery Today, 2022, 27, 490-502.	3.2	15
423	An ever-changing landscape in Roberts syndrome biology: Implications for macromolecular damage. PLoS Genetics, 2020, 16, e1009219.	1.5	8
424	Thalidomide tragedy, 1950s. , 2022, , 165-175.		3



#	ARTICLE	IF	CITATIONS
425	The Stability of Misperceptions under Mutations. SSRN Electronic Journal, 0, , .	0.4	0
426	Targeted therapy in melanoma. <i>Biologics: Targets and Therapy</i> , 2009, 3, 475-84.	3.0	12
427	Inhibitory effects of thalidomide on bleomycin-induced pulmonary fibrosis in rats via regulation of thioredoxin reductase and inflammations. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 4390-4401.	0.0	7
428	Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme. <i>JAMA Dermatology</i> , 2021, 157, 1472.	2.0	5
429	Therapeutic Interventions Targeting Innate Immune Receptors: A Balancing Act. <i>Chemical Reviews</i> , 2022, 122, 3414-3458.	23.0	10
430	Evaluation of Polymorphisms in Toll-Like Receptor Genes as Biomarkers of the Response to Treatment of Erythema Nodosum Leprosum. <i>Frontiers in Medicine</i> , 2021, 8, 713143.	1.2	4
431	Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 794997.	1.6	39
432	Idiopathic pulmonary fibrosis: Current and future treatment. <i>Clinical Respiratory Journal</i> , 2022, 16, 84-96.	0.6	77
433	Targeting NF- $\kappa$ B Signaling in Cancer Stem Cells: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 261.	1.4	11
435	The Immunomodulating Effects of Thalidomide and Dexamethasone in a Murine Cardiac Allograft Transplantation Model. <i>Yonsei Medical Journal</i> , 2022, 63, 158.	0.9	0
436	Introduction and Historical Overview of Drug Repurposing Opportunities. <i>RSC Drug Discovery Series</i> , 2022, , 1-13.	0.2	4
437	Geotemporospatial and causal inference epidemiological analysis of US survey and overview of cannabis, cannabidiol and cannabinoid genotoxicity in relation to congenital anomalies 2001â€“2015. <i>BMC Pediatrics</i> , 2022, 22, 47.	0.7	31
438	The Application of Brain Organoids in Assessing Neural Toxicity. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 799397.	1.4	11
440	Toxicologic pathology of the reproductive system. , 2022, , 1289-1321.		0
441	Emerging mechanisms of targeted protein degradation by molecular glues. <i>Methods in Cell Biology</i> , 2022, , .	0.5	1
443	DREAMTIME NMR Spectroscopy: Targeted Multiâ€“Compound Selection with Improved Detection Limits. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	13
444	DREAMTIME NMR Spectroscopy: Targeted Multiâ€“Compound Selection with Improved Detection Limits. <i>Angewandte Chemie</i> , 0, , .	1.6	3
445	Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China. <i>Frontiers in Immunology</i> , 2022, 13, 825367.	2.2	20



#	ARTICLE	IF	CITATIONS
446	Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways. <i>Bioengineered</i> , 2022, 13, 6579-6589.	1.4	21
447	Nanostructured materials for circular dichroism and chirality at the nanoscale: towards unconventional characterization. <i>Optical Materials Express</i> , 0, , .	1.6	6
448	Identification of inflammatory regulation roles of thalidomide/ruxolitinib in nucleus pulposus and construction of polyelectrolyte nanocomplexes-impregnated injectable hydrogels for synergistic intervertebral disk degeneration treatment. <i>Nano Today</i> , 2022, 44, 101462.	6.2	7
449	Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial. <i>Cancer</i> , 2022, 128, 1467-1474.	2.0	9
450	Ikars Proteins in Tumor: Current Perspectives and New Developments. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 788440.	1.6	5
451	Drug Repurposing for Influenza Virus Polymerase Acidic (PA) Endonuclease Inhibitor. <i>Molecules</i> , 2021, 26, 7326.	1.7	3
452	Targeted therapy in melanoma. <i>Biologics: Targets and Therapy</i> , 2009, 3, 475.	3.0	4
453	Anti-TNF- $\alpha$ Therapy as a Potential Treatment for Comorbid Pain in Post-traumatic Stress Disorder. <i>Douleur Et Analgesie</i> , 2022, 35, 59-62.	0.2	0
454	Antimicrobial-resistant <i>Neisseria gonorrhoeae</i> can be targeted using inhibitors against evolutionary conserved asparaginase. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1171-1182.	1.2	3
455	First Asymmetric Synthesis of Passerini-Type Condensation Products in Water Using Pregabalin: A Chiral Amino Acid for the Efficient Asymmetric Induction. <i>ChemistrySelect</i> , 2022, 7, .	0.7	3
456	Implications of sex-specific differences on clinical studies of human health. , 2022, , 11-33.		0
457	Thalidomide Alleviates Pulmonary Fibrosis Induced by Silica in Mice by Inhibiting ER Stress and the TLR4-NF- $\kappa$ B Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5656.	1.8	5
458	Effect of Chiral Purity on Adjuvanticity of Archaeol-Based Glycolipids. <i>Journal of Medicinal Chemistry</i> , 0, , .	2.9	2
459	( <i>S</i> )- $\beta$ -aminopiperidine-2,6-dione is a biosynthetic intermediate of microbial blue pigment indigoidine. , 0, , .		0
460	A review on chiral metal-organic frameworks: synthesis and asymmetric applications. <i>Nanoscale</i> , 2022, 14, 13405-13427.	2.8	22
461	On the Chirality of Drugs and the Structures of Biomacromolecules. <i>Biophysics (Russian Federation)</i> , 2022, 67, 374-385.	0.2	0
462	Whole-exome sequencing and bioinformatics analysis of a case of non-alpha-fetoprotein-elevated lung hepatoid adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
463	Metasurface Micro/Nano-Optical Sensors: Principles and Applications. <i>ACS Nano</i> , 2022, 16, 11598-11618.	7.3	80

#	ARTICLE	IF	CITATIONS
464	Deracemisation and stereoinversion by a nanoconfined bidirectional enzyme cascade: dual control by electrochemistry and selective metal ion activation. <i>Chemical Communications</i> , 2022, 58, 11713-11716.	2.2	1
465	Chiral Biomaterials for Nanomedicines: From Molecules to Supraparticles. <i>Pharmaceutics</i> , 2022, 14, 1951.	2.0	5
466	Revisiting potential value of antitumor drugs in the treatment of COVID-19. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	1
467	The efficacy and safety of thalidomide in the treatment of refractory Crohn's disease in adults: a double-center, double-blind, randomizedâ€“controlled trial. <i>Gastroenterology Report</i> , 2022, 10, .	0.6	1
468	Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100138.	1.7	6
469	Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	10
470	Socioeconomic, Ethnocultural, Substance- and Cannabinoid-Related Epidemiology of Down Syndrome USA 1986â€“2016: Combined Geotemporospatial and Causal Inference Investigation. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 13340.	1.2	2
471	Antidepressant Drug Sertraline against Human Cancer Cells. <i>Biomolecules</i> , 2022, 12, 1513.	1.8	7
472	A metagenome-wide association study of the gut microbiota in recurrent aphthous ulcer and regulation by thalidomide. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
473	Experimental design optimization for the synthesis of lenalidomide nitro precursor. <i>Research on Chemical Intermediates</i> , 0, , .	1.3	0
474	A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
475	Gastrointestinal bleeding in patients with continuousâ€“flow left ventricular assist devices: A comprehensive review. <i>Artificial Organs</i> , 2023, 47, 12-23.	1.0	6
476	Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting. <i>European Journal of Pharmacology</i> , 2022, 936, 175379.	1.7	8
477	Chiral plasmonic Auâ€“Ag core shell nanobipyramid for SERS enantiomeric discrimination of biologically relevant small molecules. <i>Analytica Chimica Acta</i> , 2023, 1239, 340740.	2.6	4
478	Fortuitous discoveries in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 226-230.	1.3	1
479	Molecular chirality from the viewpoint of Mueller ellipsometry. , 2022, , .		0
480	Updates on immunological mechanistic insights and targeting of the oral lichen planus microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
481	Central Neurotoxicity of Chemotherapy. , 2023, , 1-27.		0

#	ARTICLE	IF	CITATIONS
482	PLGA Nanoparticles Containing VCAM-1 Inhibitor Succinobucol and Chemotherapeutic Doxorubicin as Therapy against Primary Tumors and Their Lung Metastases. <i>Pharmaceutics</i> , 2023, 15, 349.	2.0	2
483	Treatment Modalities of Ankylosing Spondylitis. , 0, , .		0
484	Axisymmetric bis-tridentate Ir( <i>iii</i> ) photoredox catalysts for anticancer phototherapy under hypoxia. <i>Chemical Communications</i> , 2023, 59, 3083-3086.	2.2	5
485	Central Neurotoxicity of Chemotherapy. , 2023, , 1-27.		0
486	Immunotherapy for Multiple Myeloma. , 2023, , 1-22.		0
487	Clinical characteristics and risk factors of ovarian reserve decreases in women with Crohn's disease: a case-control study. <i>Journal of Ovarian Research</i> , 2023, 16, .	1.3	1
488	Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). <i>Journal of Clinical Immunology</i> , 2023, 43, 780-793.	2.0	2
489	Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 2904-2917.	2.9	13
490	Enantioseparation Membranes: Research Status, Challenges, and Trends. <i>Small</i> , 2023, 19, .	5.2	8
491	A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	7
492	Augmentation of Pectoral Fin Teratogenicity by Thalidomide in Human Cytochrome P450 3A-Expressing Zebrafish. <i>Pharmaceutics</i> , 2023, 16, 368.	1.7	1
493	Phthalimides Represent a Promising Scaffold for Multi-Targeted Anticancer Agents. <i>ChemistrySelect</i> , 2023, 8, .	0.7	4
494	Successful Switch to Adalimumab after Long-Term Thalidomide-Based Maintenance Therapy for Juvenile Onset Intestinal Behçet's Disease: A Case Report. <i>Journal of St Marianna University</i> , 2022, 13, 149-154.	0.1	0
495	Aptamer-Based Targeted Protein Degradation. <i>ACS Nano</i> , 2023, 17, 6150-6164.	7.3	17
496	Evolution in biomechanics. , 2023, , 495-663.		0
497	Zebrafish in Drug Discovery: Safety Assessment. , 2022, , 1-21.		0
498	Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy. <i>Pharmaceutics</i> , 2023, 15, 1074.	2.0	3
499	Whole-cell-catalyzed hydrogenation/deuteration of aryl halides with a genetically repurposed photodehalogenase. <i>CheM</i> , 2023, 9, 1897-1909.	5.8	4

#	ARTICLE	IF	CITATIONS
500	Targeted therapy. , 2023, , 205-411.		0
503	Regulation of biological processes by intrinsically chiral engineered materials. Nature Reviews Materials, 2023, 8, 403-413.	23.3	12
515	Molecular Glue Discovery: Current and Future Approaches. Journal of Medicinal Chemistry, 2023, 66, 9278-9296.	2.9	11
521	A facile synthesis of phthalimides from <i>o</i> -phthalaldehyde and amines <i>via</i> tandem cyclocondensation and $\text{H}^+$ oxidation by an electrochemical oxygen reduction reaction. Organic and Biomolecular Chemistry, 2023, 21, 7707-7711.	1.5	0
526	Thalidomid: Fluch, Segen und Triumph eines Schlafmittels. , 2023, , 137-150.		0